Ipsen 2023 Integrated Annual Report
Delivering on our strategy
Transforming Ipsen for sustainable growth
Over the past three years, we have shifted from reliance on a single blockbuster to four growth platforms. In 2023, we further enriched our portfolio with the acquisition of Albireo, and since 2020, we’ve added more than 25 new programs to our pipeline.
Our growth has been possible thanks to the efficiencies we have generated, which we have reinvested in expanding our pipeline and launching new medicines.
2023 marked the beginning of a new phase of growth. With four potential launches in 2024, we are focused on excellence, execution and rapidity. Our progress to date demonstrates that our strategy is delivering, leading to a stronger, more resilient Ipsen.
2023 in review
We are reaching more people living with high unmet medical need than ever before, while delivering strong financial performance and putting in place the building blocks for future sustainable success.
3,128M
total sales
+13%*
revenue in growth platforms in 2023
* At constant exchange rates
€2,346M
2023 Oncology sales
€125.1M
2023 Rare Disease sales
€656.9M
2023 Neuroscience sales
Our strategy
We bring the full potential of our medicines to patients by building a high-value, sustainable pipeline and delivering efficiencies to enable targeted investments and growth. Our approach is underpinned by our culture of collaboration and excellence.
Innovation
We continue to accelerate innovation through partnership to bring first- or best-in-class treatments to patients around the world. Our rapid scale-up model enables us to execute with precision and focus.
Pipeline
Our pipeline growth is fueled by external innovation and underpinned by our research capabilities and clinical development expertise. We have acquired, partnered and in-licensed along the development continuum and across Oncology, Rare Disease and Neuroscience.
Sustainable Growth
We are strengthening and expanding our pipeline at every stage of development to drive sustainable growth. In 2023, we invested €619 million in R&D, shaping the future of how we support patients.
Download our 2023 Integrated Annual Report to learn more about out our strategy
Innovation for Patients
Focused on excellence, our 700 R&D employees and our external partners are progressing our pipeline of innovations to bring new treatments to patients across our three therapeutic areas.
Oncology
For more than 35 years, Oncology has been the foundation of our business and remains at the core of our strategy. It accounted for three quarters of Ipsen’s total sales in 2023.
Rare disease
For three decades, Ipsen has fostered a patient-first, science-led, data-driven mindset to improve the health and prolong the lives of people living with rare diseases.
Neuroscience
Leveraging world-class research facilities and 30 years of clinical experience, Ipsen continues to advance neurotoxin innovation for clinical and aesthetic indications.
My hope for the future is that people with primary biliary cholangitis can get diagnosed more easily. I want people to understand it more… and of course, that there will also be a cure.
Generation Ipsen
Generation Ipsen is both the bedrock and the conduit for our sustainability efforts. Through our Generation Ipsen strategy, we set ambitious goals across four pillars, aiming to drive positive action and leave a lasting impact for a better and healthier world.
Fondation Ipsen
Fondation Ipsen improves the lives of people living with rare diseases by contributing to advances in scientific research and policy. In 2023, Fondation Ipsen’s publishing division, BookLab, published 27 new educational books focused on rare diseases and disability.